Tracking the latest research and clinical advances in stem cell exosome therapy
A research team led by Professor Chang Zhijie from the School of Basic Medical Sciences, Tsinghua University, in collaboration with the PLA General Hospital and other institutions, has published landmark findings in the prestigious journal Signal Transduction and Targeted Therapy (a Nature sub-journal), demonstrating that inhaled human umbilical cord mesenchymal stem cell exosomes (hUCMSC-EVs) can safely and effectively reverse pulmonary fibrosis.
A 42-year-old female patient with a solitary ground-glass nodule (approximately 8mm in diameter) in the outer basal segment of the left lower lobe, after 3 months of ineffective anti-inflammatory treatment, underwent umbilical cord mesenchymal stem cell exosome nebulization therapy. The lesion was completely absorbed after 17 days.
The research group led by Professor Chang Zhijie at Tsinghua University School of Medicine has developed a method of treating pulmonary fibrosis through inhaled extracellular vesicles (exosomes) derived from umbilical cord mesenchymal stem cells, and has completed the world's first Phase I clinical trial in this field.
Detailed instructions for JuvGuard exosome nebulization products, including thawing methods, nebulization procedures, precautions, and recommended treatment cycles.